Spruce Biosciences, Inc. (SPRB) stock
SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/30
$40.84+0.35 (+0.86%)
Close on Nov 18, 2026Market cap $117.37MP/E –Yield –
Spruce Biosciences total assets
Total assets on the balance sheet at the end of each period.
Spruce Biosciences's total assets was $102.85M at Jun 30, 2026. For fiscal 2025 it was $53.02M, up 17.3% from the year before. The highest annual figure on record is $162.88M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.02M | +17.3% |
| FY2024 | Dec 31, 2024 | $45.21M | -56.5% |
| FY2023 | Dec 31, 2023 | $103.95M | +21.4% |
| FY2022 | Dec 31, 2022 | $85.65M | -32.3% |
| FY2021 | Dec 31, 2021 | $126.49M | -22.3% |
| FY2020 | Dec 31, 2020 | $162.88M | +3371.5% |
| FY2019 | Dec 31, 2019 | $4.69M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $102.85M | +371.4% |
| Q1 FY2026 | Mar 31, 2026 | $56.17M | +77.5% |
| Q4 FY2025 | Dec 31, 2025 | $53.02M | +17.3% |
| Q3 FY2025 | Sep 30, 2025 | $15.31M | -76.5% |
| Q2 FY2025 | Jun 30, 2025 | $21.82M | -71.1% |
| Q1 FY2025 | Mar 31, 2025 | $31.65M | -63.8% |
| Q4 FY2024 | Dec 31, 2024 | $45.21M | -56.5% |
| Q3 FY2024 | Sep 30, 2024 | $65.10M | -42.4% |
| Q2 FY2024 | Jun 30, 2024 | $75.52M | -40.0% |
| Q1 FY2024 | Mar 31, 2024 | $87.54M | -37.1% |
| Q4 FY2023 | Dec 31, 2023 | $103.95M | +21.4% |
| Q3 FY2023 | Sep 30, 2023 | $112.99M | +18.6% |
| Q2 FY2023 | Jun 30, 2023 | $125.96M | +20.5% |
| Q1 FY2023 | Mar 31, 2023 | $139.11M | +21.0% |
| Q4 FY2022 | Dec 31, 2022 | $85.65M | -32.3% |
| Q3 FY2022 | Sep 30, 2022 | $95.30M | -29.5% |
| Q2 FY2022 | Jun 30, 2022 | $104.52M | -27.1% |
| Q1 FY2022 | Mar 31, 2022 | $114.99M | -25.3% |
| Q4 FY2021 | Dec 31, 2021 | $126.49M | -22.3% |
| Q3 FY2021 | Sep 30, 2021 | $135.09M | +72.1% |
| Q2 FY2021 | Jun 30, 2021 | $143.45M | +2957.3% |
| Q1 FY2021 | Mar 31, 2021 | $153.99M | – |
| Q4 FY2020 | Dec 31, 2020 | $162.88M | – |
| Q3 FY2020 | Sep 30, 2020 | $78.49M | – |
| Q4 FY2019 | Dec 31, 2019 | $4.69M | – |
See a number that looks wrong?